Passage BIO, Inc. - Common Stock, par value $0.0001 per share (PASG)

CUSIP: 702712209

Q3 2026 13F Holders as of 30 Sep 2026

Holder snapshot 5 signals
Share change
+12
SEC-reported price per share
$4.50
Number of holders
3
Value change
+$54
Number of buys
1
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
3,219,973

Security key

702712209

Report period

Q3 2026

Institutions

3

Top holders

3

Ownership snapshot

Top reported holders of PASG - Passage BIO, Inc. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
Lynx1 Capital Management LP
Disclosed value leader
Lynx1 Capital Management LP
Comparable rows
4/15
Latest evidence
30 Jun 2026
13F 13D/G 3/4/5 Lead comparable stake: 21% 11 rows are not safely comparable across share classes. 13D/G row: Lynx1 Capital Management LP Showing 1-6 of 15 holder rows.

Quick read

Lynx1 Capital Management LP leads the comparable SEC ownership view at 21%.

4 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Lynx1 Capital Management LP's linked filing trail.
Comparable ownership Top 4
Lynx1 Capital Management LP 21%
Baselake Partners, LP 7.3%
Erste Asset Management GmbH 4.4%
ORBIMED ADVISORS LLC 4.2%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
Lynx1 Capital Management LP
13F 13D/G 3/4/5
Company · 10%+ Owner
21%
Reported 13D/G · 25 Jun 2026
$3,287,942
673,759 shares
— 30 Jun 2026
Baselake Partners, LP
13D/G
7.3%
Reported 13D/G · 18 Jun 2026
$1,203,497
235,058 shares
$0 18 Jun 2026
Erste Asset Management GmbH
13D/G 13F
Company
4.4%
Reported 13D/G · 31 Mar 2024
$810,414
2,455,800 shares
-$166,650 31 Mar 2024
ORBIMED ADVISORS LLC
3/4/5 13D/G
10%+ Owner
4.2%
Reported 13D/G · 22 Jul 2025
$2,001,893
6,066,343 shares
— 24 Jun 2025
Weston Nichols
3/4/5
10%+ Owner
—
denominator unverified
$2,774,202
673,759 shares
+$206,101 25 Jun 2026
Thomas Woiwode
3/4/5
Director, 10%+ Owner
—
denominator unverified
—
24,000 shares
— 25 May 2023
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q3 2026

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
3
Shares
52,207
Rows available
3
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q3 2026 vs Q2 2026 Across Filers

Q2 2026 holders
28
Q3 2026 holders
3
Holder diff
-25
Investor Q2 2026 Shares Q3 2026 Shares Share Diff Share Chg % Q2 2026 value Q3 2026 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .